Mycophenolic sodium (EC-MPS) is an enteric coated formulation of mycophenolate acid tablets that delivers the active moiety mycophenolic acid (MPA). EC-MPS was formulated in an attempt to overcome the upper GI adverse reactions associated with Mycophenolate mofetil (MMF). MPA is an immunosuppressant, non-competitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. T-and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines. EC-MPS has demonstrated equivalent efficacy & safety compared to MMF.
In combination with cyclosporine and corticosteroids for the prophylaxis of organ rejection in adult patients receiving an allogeneic kidney transplant.
Prophylaxis of organ rejection in paediatric patients 5 years of age and older who are at least 6 months post kidney transplant.